Literature DB >> 24114568

Breast cancer statistics, 2013.

Carol DeSantis1, Jiemin Ma, Leah Bryan, Ahmedin Jemal.   

Abstract

In this article, the American Cancer Society provides an overview of female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Approximately 232,340 new cases of invasive breast cancer and 39,620 breast cancer deaths are expected to occur among US women in 2013. One in 8 women in the United States will develop breast cancer in her lifetime. Breast cancer incidence rates increased slightly among African American women; decreased among Hispanic women; and were stable among whites, Asian Americans/Pacific Islanders, and American Indians/Alaska Natives from 2006 to 2010. Historically, white women have had the highest breast cancer incidence rates among women aged 40 years and older; however, incidence rates are converging among white and African American women, particularly among women aged 50 years to 59 years. Incidence rates increased for estrogen receptor-positive breast cancers in the youngest white women, Hispanic women aged 60 years to 69 years, and all but the oldest African American women. In contrast, estrogen receptor-negative breast cancers declined among most age and racial/ethnic groups. These divergent trends may reflect etiologic heterogeneity and the differing effects of some factors, such as obesity and parity, on risk by tumor subtype. Since 1990, breast cancer death rates have dropped by 34% and this decrease was evident in all racial/ethnic groups except American Indians/Alaska Natives. Nevertheless, survival disparities persist by race/ethnicity, with African American women having the poorest breast cancer survival of any racial/ethnic group. Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment to all segments of the population.
© 2013 American Cancer Society, Inc.

Entities:  

Keywords:  breast neoplasms; epidemiology; health disparities; screening and early detection

Mesh:

Substances:

Year:  2013        PMID: 24114568     DOI: 10.3322/caac.21203

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  831 in total

Review 1.  PIM1: a promising target in patients with triple-negative breast cancer.

Authors:  Wen Zhao; RuiYue Qiu; Pan Li; Jin Yang
Journal:  Med Oncol       Date:  2017-07-18       Impact factor: 3.064

2.  Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.

Authors:  Albert J Farias; Xianglin L Du
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-17       Impact factor: 4.254

3.  Discovery of mutations in homologous recombination genes in African-American women with breast cancer.

Authors:  Yuan Chun Ding; Aaron W Adamson; Linda Steele; Adam M Bailis; Esther M John; Gail Tomlinson; Susan L Neuhausen
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

4.  Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: Data from the Patient Navigation Research Program.

Authors:  Ambili Ramachandran; Frederick R Snyder; Mira L Katz; Julie S Darnell; Donald J Dudley; Steven R Patierno; Mechelle R Sanders; Patricia A Valverde; Melissa A Simon; Victoria Warren-Mears; Tracy A Battaglia
Journal:  Cancer       Date:  2015-08-19       Impact factor: 6.860

5.  Multiplexed Molecular Imaging of Fresh Tissue Surfaces Enabled by Convection-Enhanced Topical Staining with SERS-Coded Nanoparticles.

Authors:  Yu W Wang; Josh D Doerksen; Soyoung Kang; Daniel Walsh; Qian Yang; Daniel Hong; Jonathan T C Liu
Journal:  Small       Date:  2016-08-29       Impact factor: 13.281

Review 6.  Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.

Authors:  Sakshi Jasra; Jesus Anampa
Journal:  Curr Treat Options Oncol       Date:  2018-05-11

7.  Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer.

Authors:  Gaochen Lan; Jie Li; Qiaomei Wen; Lin Lin; Libin Chen; Liyu Chen; Xi Chen
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

8.  A comparative analysis of breast cancer stage between women enrolled in the National Breast and Cervical Cancer Early Detection Program and women not participating in the program.

Authors:  Manxia Wu; Harland Austin; Christie R Eheman; Zachary Myles; Jacqueline Miller; Janet Royalty; A Blythe Ryerson
Journal:  Cancer Causes Control       Date:  2015-03-12       Impact factor: 2.506

Review 9.  Clinical utility of gene-expression signatures in early stage breast cancer.

Authors:  Maryann Kwa; Andreas Makris; Francisco J Esteva
Journal:  Nat Rev Clin Oncol       Date:  2017-05-31       Impact factor: 66.675

10.  Breast cancer in Wales: time trends and geographical distribution.

Authors:  Ganiy Opeyemi Abdulrahman
Journal:  Gland Surg       Date:  2014-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.